Social media and sensemaking patterns in new product development: demystifying the customer sentiment

Artificial intelligence by principle is developed to assist but also support decision making processes. In our study, we explore how information retrieved from social media can assist decision-making processes for new product development (NPD). We focus on consumers’ emotions that are expressed through social media and analyse the variations of their sentiments in all the stages of NPD. We collect data from Twitter that reveal consumers’ appreciation of aspects of the design of a newly launched model of an innovative automotive company. We adopt the sensemaking approach coupled with the use of fuzzy logic for text mining. This combinatory methodological approach enables us to retrieve consensus from the data and to explore the variations of sentiments of the customers about the product and define the polarity of these emotions for each of the NPD stages. The analysis identifies sensemaking patterns in Twitter data and explains the NPD process and the associated steps where the social interactions from customers can have an iterative role. We conclude the paper by outlining an agenda for future research in the NPD process and the role of the customer opinion through sensemaking mechanisms

Does primary tumor localization has prognostic importance in seminoma patients?: Turkish oncology Group study

Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients. Methods: In our study, 612 seminomatous GCT patients diagnosed in 22 centers between 01.01.1989 and 03.02.2019 were retrospectively evaluated. Patient interview information, patient files and electronic system data were used for the study. Results: The primary tumor was localized in the right testis in 305 (49.9%) patients and in 307 (50.1%) in the left testis. Mean age of the patients was 36 years (range 16-85±10.4). The median follow-up period was 47 months (1-298). Recurrence was observed in 78 (12.7%) patients and 29 (4.7%) died during the follow-up period. Four-year overall survival (OS) was 95.4% and 4-year progression-free survival (PFS) was 84.5%. The relationship between localization and relapse was significant in 197 patients with stage 2 and stage 3 (p=0.003). In this patient group, 41 (20.8%) relapses were observed. Thirty (73.2%) of the relapses were in the right testis and 11 (26.8%) in the left testis. Four-year OS was 92.1% in patients with right tumor; and 98.7% in patients with left tumor (p=0.007). When 612 patients were evaluated with a mean follow-up of 4 years, there was a 6.6% survival advantage in patients with left testicular tumor and this difference was significant (p=0.007). Conclusion: Survival rates of patients with primary right testicular localization were worse compared with left testicular localization, and relapse rates were higher in stage 2 and 3 patients with right testicular localization. © 2020 Zerbinis Publications. All rights reserved

patients?: Turkish Oncology Group Study

Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients.Methods: In our study, 612 seminomatous GCT patients diagnosed in 22 centers between 01.01.1989 and 03.02.2019 were retrospectively evaluated. Patient interview information, patient files and electronic system data were used for the study.Results: The primary tumor was localized in the right testis in 305 (49.9%) patients and in 307 (50.1%) in the left testis. Mean age of the patients was 36 years (range 16-85 +/- 10.4).The median follow-up period was 47 months (1-298). Recurrence was observed in 78 (127%) patients and 29 (4.7%) died during the follow-up period. Four-year overall survival (OS) was 95.4% and 4-year progression-free survival (PFS) was 84.5%. The relationship between localization and relapse was significant in 197 patients with stage 2 and stage 3 (p=0.003). In this patient group, 41 (20.8%) relapses were observed. Thirty (73.2%) of the relapses were in the right testis and 11 (26.8%) in the left testis.Four-year OS was 92.1% in patients with right tumor; and 98.7% in patients with left tumor (p=0.007). When 612 patients were evaluated with a mean follow-up of 4 years, there was a 6.6% survival advantage in patients with left testicular tumor and this difference was significant (p=0.007).Conclusion: Survival rates of patients with primary right testicular localization were worse compared with left testicular localization, and relapse rates were higher in stage 2 and 3 patients with right testicular localization.C1 [Yildiz, Birol; Erturk, Ismail; Acar, Ramazan; Karadurmus, Nuri] Hlth Sci Univ, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Kucukarda, Ahmet; Gokyer, Ali] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey.[Demiray, Atike Gokcen] Pamukkale Univ, Fac Med, Dept Med Oncol, Denizli, Turkey.[Paydas, Semra] Cukurova Univ, Fac Med, Dept Med Oncol, Adana, Turkey.[Aral, Ipek Pinar] Nevsehir State Hosp, Dept Radiat Oncol, Nevsehir, Turkey.[Gumusay, Ozge] Gazi Osman Pasa Univ, Fac Med, Dept Med Oncol, Tokat, Turkey.[Bilici, Ahmet] Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey.[Akdeniz, Nadiye] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkey.[Bahceci, Aykut] Gaziantep Dr Ersin ARSLAN Training & Res Hosp, Dept Med Oncol, Gaziantep, Turkey.[Demir, Hacer] Afyon Kocatepe Univ, Fac Med, Dept Med Oncol, Afyon, Turkey.[Esin, Ece] Bayindir Hosp, Dept Med Oncol, Ankara, Turkey.[Uyeturk, Ummugul] Abant Izzet Baysal Univ, Fac Med, Dept Med Oncol, Bolu, Turkey.[Okten, Ilker Nihat] Istanbul Medeniyet Univ, Gortepe Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey.[Turk, H. Mehmet] BezmiAlem Vakif Univ, Dept Med Oncol, Istanbul, Turkey.[Topaloglu, Ulas Serkan] Kayseri City Hosp, Dept Internal Med, Kayseri, Turkey.[Basoglu, Tugba] Marmara Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey.[Turhal, Nazim Serdar] Anadolu Med Ctr, Dept Med Oncol, Kocaeli, Turkey.[Cinkir, Havva Yesil] Gaziantep Univ, Dept Med Oncol, Fac Med, Gaziantep, Turkey.[Menekse, Serkan; Kut, Engin] Manisa City Hosp, Dept Med Oncol, Manisa, Turkey.[Cakmak, Yagmur] Kocaeli Univ, Fac Med, Dept Med Oncol, Kocaeli, Turkey.[Urun, Yuksel] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkey.[Dal, Pinar] Eskisehir City Hosp, Dept Med Oncol, Eskisehir, Turkey.[Sakalar, Teoman] Kahramanmaras City Hosp, Dept Med Oncol, Kahramanmaras, Turkey.[Aktepe, Oktay Halit] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey